180 related articles for article (PubMed ID: 37599366)
41. Sequential analysis of transcript expression patterns improves survival prediction in multiple cancers.
Mandel J; Avula R; Prochownik EV
BMC Cancer; 2020 Apr; 20(1):297. PubMed ID: 32264880
[TBL] [Abstract][Full Text] [Related]
42. Revealing metastatic castration-resistant prostate cancer master regulator through lncRNAs-centered regulatory network.
Ferraz RS; Cavalcante JVF; Magalhães L; Ribeiro-Dos-Santos Â; Dalmolin RJS
Cancer Med; 2023 Sep; 12(18):19279-19290. PubMed ID: 37644825
[TBL] [Abstract][Full Text] [Related]
43. Construction and validation of a signature for T cell-positive regulators related to tumor microenvironment and heterogeneity of gastric cancer.
Guo Y; Zhang Y; Cen K; Dai Y; Mai Y; Hong K
Front Immunol; 2023; 14():1125203. PubMed ID: 37711621
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
45. Interplay of four types of RNA modification writers revealed distinct tumor microenvironment and biological characteristics in pancreatic cancer.
Gao W; Chen D; Liu J; Zang L; Xiao T; Zhang X; Li Z; Zhu H; Yu X
Front Immunol; 2022; 13():1031184. PubMed ID: 36601127
[TBL] [Abstract][Full Text] [Related]
46. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
47. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
[TBL] [Abstract][Full Text] [Related]
48. Role of nitric oxide in pancreatic cancer cells exhibiting the invasive phenotype.
Fujita M; Somasundaram V; Basudhar D; Cheng RYS; Ridnour LA; Higuchi H; Imadome K; No JH; Bharadwaj G; Wink DA
Redox Biol; 2019 Apr; 22():101158. PubMed ID: 30852389
[TBL] [Abstract][Full Text] [Related]
49. Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.
Zhang S; Jing Y; Zhang M; Zhang Z; Ma P; Peng H; Shi K; Gao WQ; Zhuang G
Sci Rep; 2015 Nov; 5():16066. PubMed ID: 26530441
[TBL] [Abstract][Full Text] [Related]
50. Master Transcription Regulators and Transcription Factors Regulate Immune-Associated Differences Between Patients of African and European Ancestry With Colorectal Cancer.
Myer PA; Kim H; Blümel AM; Finnegan E; Kel A; Thompson TV; Greally JM; Prehn JH; O'Connor DP; Friedman RA; Floratos A; Das S
Gastro Hep Adv; 2022; 1(3):328-341. PubMed ID: 35711675
[TBL] [Abstract][Full Text] [Related]
51. Identification of upstream regulators for prognostic expression signature genes in colorectal cancer.
Bae T; Rho K; Choi JW; Horimoto K; Kim W; Kim S
BMC Syst Biol; 2013 Sep; 7():86. PubMed ID: 24006872
[TBL] [Abstract][Full Text] [Related]
52. A global immune gene expression signature for human cancers.
Liu Y
Oncotarget; 2019 Mar; 10(20):1993-2005. PubMed ID: 30956779
[TBL] [Abstract][Full Text] [Related]
53. Identification of a brand intratumor microbiome signature for predicting prognosis of hepatocellular carcinoma.
Song Y; Xiang Z; Lu Z; Su R; Shu W; Sui M; Wei X; Xu X
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11319-11332. PubMed ID: 37380815
[TBL] [Abstract][Full Text] [Related]
54. Comprehensive Analysis of m
Wu J; Hou C; Wang Y; Wang Z; Li P; Wang Z
Int J Genomics; 2021; 2021():3803724. PubMed ID: 34631874
[TBL] [Abstract][Full Text] [Related]
55. Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
Wahdan-Alaswad R; Harrell JC; Fan Z; Edgerton SM; Liu B; Thor AD
Cell Cycle; 2016; 15(8):1046-59. PubMed ID: 26919310
[TBL] [Abstract][Full Text] [Related]
56. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
57. Genome-wide identification of CpG island methylator phenotype related gene signature as a novel prognostic biomarker of gastric cancer.
Zeng Z; Xie D; Gong J
PeerJ; 2020; 8():e9624. PubMed ID: 32821544
[TBL] [Abstract][Full Text] [Related]
58. Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers.
Cohen AL; Piccolo SR; Cheng L; Soldi R; Han B; Johnson WE; Bild AH
BMC Med Genomics; 2013 Sep; 6():35. PubMed ID: 24079712
[TBL] [Abstract][Full Text] [Related]
59. Multiscale network analysis reveals molecular mechanisms and key regulators of the tumor microenvironment in gastric cancer.
Song WM; Lin X; Liao X; Hu D; Lin J; Sarpel U; Ye Y; Feferman Y; Labow DM; Walsh MJ; Zheng X; Zhang B
Int J Cancer; 2020 Mar; 146(5):1268-1280. PubMed ID: 31463974
[TBL] [Abstract][Full Text] [Related]
60. Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer.
Ucaryilmaz Metin C; Ozcan G
BMC Cancer; 2022 Jun; 22(1):692. PubMed ID: 35739492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
